title: Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine.
authors: G
authors: G
authors: Jaeger
authors: F
authors: F
authors: Bauer
authors: R
authors: R
authors: Brezinschek
authors: C
authors: C
authors: Beham-Schmid
authors: C
authors: C
authors: Mannhalter
authors: P
authors: P
authors: Neumeister
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000743:Anemia, Hemolytic / Q000209:etiology / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001803:Blood Transfusion; D017338:Cladribine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D016399:Lymphoma, T-Cell / Q000150:complications / Q000188:drug therapy*; D009503:Neutropenia / Q000209:etiology; D011239:Prednisolone / Q000008:administration & dosage; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D013160:Splenic Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D016692:Receptors, Antigen, T-Cell, gamma-delta; D000074323:Alemtuzumab; D017338:Cladribine; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone